Skip to content

AAT + tDCS to Reduce Cue-induced Craving and Smoking Behavior

AAT + tDCS to Reduce Cue-induced Craving and Smoking Behavior

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05426460
Enrollment
41
Registered
2022-06-22
Start date
2022-04-29
Completion date
2024-06-14
Last updated
2025-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smoking Behaviors, Smoking, Cigarette

Keywords

Transcranial Direct Current Stimulation (tDCS), Approach Avoidance Task (AAT), Smoking

Brief summary

Smokers are highly reactive to smoking-related stimuli and report that this cue reactivity (CR) is a major obstacle to quitting. To date, no pharmacologic methods attenuate CR, and attempts to diminish it with traditional cue exposure treatment (CET) have not proven effective. The proposed study will test a highly novel cue-based smoking treatment adjunct combining an Approach/Avoidance Task (AAT) with brain stimulation via tDCS applied to the dorsolateral prefrontal cortex (dlPFC) during personalized multi-cue exposure; the goal of which is to discover an effective means of reducing cue reactivity and daily smoking, and increasing intent and confidence to quit, among high treatment-interest smokers.

Detailed description

Exposure to smoking-related cues robustly increases self-report craving and immediate subsequent smoking. This cue-reactivity (CR) is an often-reported obstacle to quitting among smokers. Unlike methods to diminish abstinence-induced craving, which have been highly successful with the advent of nicotine replacement therapies (NRTs), pharmacotherapies have not been shown to diminish smoking-related reactivity to cues. Past behavioral methods to reduce smokers' CR, most commonly extinction training through cue-exposure treatment (CET), have also consistently failed. Review of past CET studies reveals that this failure is largely due to several methodological shortcomings including: (1) presenting only proximal cues (e.g., cigarettes, ashtrays), (2) conducting passive unreinforced exposure to these limited cues, and (3) achieving only limited new learning. The researchers extensive past cue work makes them uniquely qualified to remedy these flaws by designing and testing novel CET methodology incorporating contemporary techniques and technology to reduce CR and relieve smokers of this ubiquitous source of relapse risk. The researchers propose three methods to improve CET. First, using well-tested methods for personalizing smoking cues and presenting numerous proximal, environment, and people cues in combination, the proposed cue exposure will better capture and target the cue-rich situations most likely to trigger smokers' strongest CR. Second, rather than repeated passive unreinforced exposure to cues, smokers will engage in active re-training of approach biases toward their personal smoking stimuli using an Approach/Avoidance Task (AAT), a method shown to activate the dorsolateral prefrontal cortex (dlPFC), a brain region associated with both cognitive control over craving and deactivation of drug reward systems. Third, to enhance new learning, smokers will undergo non-invasive transcranial direct current brain stimulation (i.e., tDCS) of the dlPFC. Although the researchers propose each method, AAT and tDCS, should independently reduce smokers' CR to their most salient cues, providing AAT with simultaneous tDCS (AAT+tDCS) should synergistically attenuate CR by better increasing cortical excitability in the dlPFC. To assess this, a 2 x 2 active and sham-controlled test of AAT and tDCS during personalized multi-cue exposures will be used to examine pre-post training changes across several measures of smoking-related cue reactivity (cue-induced craving, cue-provoked smoking topography, and attentional bias measures of Evoked Response Potentials (ERPs) and reaction time), as well as changes in daily smoking and confidence and intent to quit pre-post training and at 1 week and 1-month follow up. The goal of this work is to develop an efficacious treatment adjunct that better prepares smokers to confront cues when they try to remain quit.

Interventions

BEHAVIORALApproach/Avoidance Task

The Approach/avoidance task (AAT) training is done using a joystick. The AAT tasks involves having participants push away pictures of smoking stimuli that appear on the screen by pushing the joystick forward, and pulling in pictures of nonsmoking stimuli that appear on the screen by pulling the joystick towards themselves. Pushing smoking-related pictures away causes the picture to shrink in size, whereas pulling a picture closer causes the picture to increase in size. This task consists of 4 blocks of 24 pictures, taking 30 minutes.

DEVICETranscranial Direct Current Stimulation

Transcranial Direct Current Stimulation active (2.0 mA) (tDCS) will be used to temporarily increase cortical excitability of the dorsolateral prefrontal cortex (dlPFC) in healthy daily smokers. Participants assigned to active tDCS conditions will receive active (2.0 mA) tDCS, with anode electrode placement over the right dlPFC and cathode electrode placement over the left bicep. tDCS will be administered the first 20 minutes of each of the five 30 minute AAT training sessions.

BEHAVIORALAC

During Active Control (AC) participants press a button on the left of right of the joystick to indicate the position the picture on a screen. Position of pictures will be balanced across the 4 blocks of 24 pictures, taking 30 minutes.

DEVICESham tDCS

Sham transcranial Direct Current Stimulation (0.1 mA) (sham tDCS) will be used as a control for active tDCS with anode electrode placement over the right dlPFC and cathode electrode placement over the left bicep. Sham tDCS will be administered during the first 20 minutes of each of the four blocks of 24 pictures, taking 30 minutes, across the 5 training sessions.

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
Cynthia Conklin
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

The transcranial tDCS is delivered without the participant or investigator knowing if they are receiving tDCS or not.

Eligibility

Sex/Gender
ALL
Age
26 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* Between the ages of 26 & 55 * High treatment interest (planning to quit within the next 6 months) * Ability to provide written informed consent * Smoke equal or greater than 7 cigarettes per day * Expired breath carbon monoxide (CO) equal or greater than 8 ppm at screening * Ability to attend 10 sessions over a 3-week period, and complete 2 follow-up phone assessments

Exclusion criteria

* Epilepsy or Current Seizure Disorder * Alcohol or Substance Dependence past 3 months (caffeine allowed, nicotine is part of inclusion criteria, alcohol \> 14 drinks per week (M) or \> 7 drinks per week (F)) * Implanted cardiac or brain medical devices * History of epilepsy or current seizure disorder * History of brain surgery or skull fracture * History of a head trauma (losing consciousness \>10 min and/or problems with speech or movement because of head injury) * Latex allergy * Scalp irritation * History of diabetes that caused loss of consciousness (\>10 min) or weakness in your arms or legs * History of electroconvulsive therapy (ECT) in the last 5 years (Y / N) History of ECT within the last 5 years * Current use of dextromethorphan * Diagnosed with or undergone treatment for alcohol or substance dependence past 3 months * Uncorrected vision deficit * Colorblindness * Use of tobacco products other than commercially available cigarettes

Design outcomes

Primary

MeasureTime frameDescription
Mean Change From Baseline in Rating Score for Intent to Quit QuestionnaireBaseline to approximately 1-weekDifference between Intent to Quit score from pre-treatment (Baseline) to post-treatment (re-test). Scale is rated 1-10 from 1= I have no thoughts about or interest in quitting smoking to 10= I have quit and will never go back A positive change score indicates an increased intention to quit.
Mean Change From Baseline in 4-item Questionnaire on Smoking Urges Craving Score During Cue Reactivity to Personal CuesBaseline to approximately 1 weekDifference between cue-induced craving rating from pre-treatment (Baseline) to post-treatment (re-test) on the questionnaire on smoking urges 4-items scored 0-100. Lower values indicate more reduction in cue-induced craving.
Mean Change From Baseline in Number Cigarettes Smoked DailyBaseline to approximately 1 weekDifference in mean number of cigarette smoker per day from pre-treatment (Baseline) to post-treatment (re-test). Lower number indicates greater reduction in cigarettes smoked.
Mean Change From Baseline in Rating Score for 5-item Confidence to Quit QuestionnaireBaseline to approximately 1-weekDifference between Confidence to Quit score from pre-treatment (Baseline) to post-treatment (re-test) scored 0-100. More positive score reflects an increase in confidence to quit smoking.

Countries

United States

Participant flow

Recruitment details

From 04/29/2022 - 5/21/2024, 179 participants were screened via telephone call. 79 passed inital phone screening and attended an in-person session in the research laboratory in a medical hospital setting where a full inclusion criteria assessment was conducted.

Pre-assignment details

Of the 79 participants who attended an inital in-person session for further screening, 23 chose not to participate in the study and 15 were deemed ineligble to continue. Forty-one participants signed informed consent and were randomized. However, 3 participants were excluded from the study after randomization leaving 38 participants contributing data and completing the study.

Participants by arm

ArmCount
AAT + tDCS
Approach Avoidance Task + Transcranial Direct Current Stimulation targeting the dorsolateral prefrontal cortex Approach/Avoidance Task: The Approach/avoidance task (AAT) training is done using a joystick. The AAT tasks involves having participants push away pictures of smoking stimuli that appear on the screen by pushing the joystick forward, and pulling in pictures of nonsmoking stimuli that appear on the screen by pulling the joystick towards themselves. Pushing smoking-related pictures away causes the picture to shrink in size, whereas pulling a picture closer causes the picture to increase in size. This task consists of 4 blocks of 24 pictures, taking 30 minutes. Transcranial Direct Current Stimulation: Transcranial Direct Current Stimulation active (2.0 mA) (tDCS) will be used to temporarily increase cortical excitability of the dorsolateral prefrontal cortex (dlPFC) in healthy daily smokers. Participants assigned to active tDCS conditions will receive active (2.0 mA) tDCS, with anode electrode placement over the right dlPFC and cathode electrode placement over the left bicep. tDCS will be administered the first 20 minutes of each of the five 30 minute AAT training sessions.
11
AAT + Sham tDCS
Approach Avoidance Task with Sham Transcranial Direct Current Stimulation. Approach/Avoidance Task: The Approach/avoidance task (AAT) training is done using a joystick. The AAT tasks involves having participants push away pictures of smoking stimuli that appear on the screen by pushing the joystick forward, and pulling in pictures of nonsmoking stimuli that appear on the screen by pulling the joystick towards themselves. Pushing smoking-related pictures away causes the picture to shrink in size, whereas pulling a picture closer causes the picture to increase in size. This task consists of 4 blocks of 24 pictures, taking 30 minutes. Sham tDCS: Sham transcranial Direct Current Stimulation (0.1 mA) (sham tDCS) will be used as a control for active tDCS with anode electrode placement over the right dlPFC and cathode electrode placement over the left bicep. Sham tDCS will be administered during the first 20 minutes of each of the four blocks of 24 pictures, taking 30 minutes, across the 5 training sessions.
9
AC + tDCS
Active Control Task with Transcranial Direct Current Stimulation targeting the dorsolateral prefrontal cortex Transcranial Direct Current Stimulation: Transcranial Direct Current Stimulation active (2.0 mA) (tDCS) will be used to temporarily increase cortical excitability of the dorsolateral prefrontal cortex (dlPFC) in healthy daily smokers. Participants assigned to active tDCS conditions will receive active (2.0 mA) tDCS, with anode electrode placement over the right dlPFC and cathode electrode placement over the left bicep. tDCS will be administered the first 20 minutes of each of the five 30 minute AAT training sessions. AC: During Active Control (AC) participants press a button on the left of right of the joystick to indicate the position the picture on a screen. Position of pictures will be balanced across the 4 blocks of 24 pictures, taking 30 minutes.
10
AC + Sham tDCS
Active Control Task with sham Transcranial Direct Current Stimulation AC: During Active Control (AC) participants press a button on the left of right of the joystick to indicate the position the picture on a screen. Position of pictures will be balanced across the 4 blocks of 24 pictures, taking 30 minutes. Sham tDCS: Sham transcranial Direct Current Stimulation (0.1 mA) (sham tDCS) will be used as a control for active tDCS with anode electrode placement over the right dlPFC and cathode electrode placement over the left bicep. Sham tDCS will be administered during the first 20 minutes of each of the four blocks of 24 pictures, taking 30 minutes, across the 5 training sessions.
8
Total38

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003
Overall StudyProtocol Violation1110

Baseline characteristics

CharacteristicAAT + tDCSAAT + Sham tDCSAC + tDCSAC + Sham tDCSTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
11 Participants9 Participants10 Participants8 Participants38 Participants
Age, Continuous44.1 years
STANDARD_DEVIATION 6.3
42.6 years
STANDARD_DEVIATION 8.7
45.8 years
STANDARD_DEVIATION 7.2
45.8 years
STANDARD_DEVIATION 7.9
44.5 years
STANDARD_DEVIATION 7.3
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants1 Participants1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
11 Participants9 Participants10 Participants7 Participants37 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
1 Participants0 Participants1 Participants0 Participants2 Participants
Race (NIH/OMB)
Black or African American
3 Participants0 Participants2 Participants2 Participants7 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants2 Participants2 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
7 Participants9 Participants7 Participants4 Participants27 Participants
Region of Enrollment
United States
11 participants9 participants10 participants8 participants38 participants
Sex: Female, Male
Female
6 Participants4 Participants5 Participants4 Participants19 Participants
Sex: Female, Male
Male
5 Participants5 Participants5 Participants4 Participants19 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 110 / 90 / 110 / 8
other
Total, other adverse events
0 / 110 / 90 / 110 / 8
serious
Total, serious adverse events
0 / 110 / 90 / 110 / 8

Outcome results

Primary

Mean Change From Baseline in 4-item Questionnaire on Smoking Urges Craving Score During Cue Reactivity to Personal Cues

Difference between cue-induced craving rating from pre-treatment (Baseline) to post-treatment (re-test) on the questionnaire on smoking urges 4-items scored 0-100. Lower values indicate more reduction in cue-induced craving.

Time frame: Baseline to approximately 1 week

Population: 3 participants (2 from AAT + tDCS and 1 from AAT + sham tDCS) were excluded from analyses due to data collection error in which their ratings were not recorded.

ArmMeasureValue (MEAN)Dispersion
AAT + tDCSMean Change From Baseline in 4-item Questionnaire on Smoking Urges Craving Score During Cue Reactivity to Personal Cues-36.5 score on a scaleStandard Deviation 20
AAT + Sham tDCSMean Change From Baseline in 4-item Questionnaire on Smoking Urges Craving Score During Cue Reactivity to Personal Cues-36.3 score on a scaleStandard Deviation 26.1
AC + tDCSMean Change From Baseline in 4-item Questionnaire on Smoking Urges Craving Score During Cue Reactivity to Personal Cues-36.6 score on a scaleStandard Deviation 34.2
AC + Sham tDCSMean Change From Baseline in 4-item Questionnaire on Smoking Urges Craving Score During Cue Reactivity to Personal Cues-22.2 score on a scaleStandard Deviation 22.8
Comparison: 2 x 2 ANOVAp-value: 0.438ANOVA
Primary

Mean Change From Baseline in Number Cigarettes Smoked Daily

Difference in mean number of cigarette smoker per day from pre-treatment (Baseline) to post-treatment (re-test). Lower number indicates greater reduction in cigarettes smoked.

Time frame: Baseline to approximately 1 week

ArmMeasureValue (MEAN)Dispersion
AAT + tDCSMean Change From Baseline in Number Cigarettes Smoked Daily-3.6 cigarettes per dayStandard Deviation 3.1
AAT + Sham tDCSMean Change From Baseline in Number Cigarettes Smoked Daily-2.6 cigarettes per dayStandard Deviation 4.7
AC + tDCSMean Change From Baseline in Number Cigarettes Smoked Daily-2.1 cigarettes per dayStandard Deviation 5.9
AC + Sham tDCSMean Change From Baseline in Number Cigarettes Smoked Daily-0.4 cigarettes per dayStandard Deviation 6.5
Comparison: 2 x 2 ANOVAp-value: 0.847ANOVA
Primary

Mean Change From Baseline in Number Cigarettes Smoked Daily

Difference in mean number of cigarettes smoked per day from pre-treatment (Baseline) to 1 week post treatment (follow-up). Lower number indicates greater reduction in cigarettes smoked.

Time frame: Baseline to approximately 2 weeks

ArmMeasureValue (MEAN)Dispersion
AAT + tDCSMean Change From Baseline in Number Cigarettes Smoked Daily-3.9 cigarettes per dayStandard Deviation 2.4
AAT + Sham tDCSMean Change From Baseline in Number Cigarettes Smoked Daily-3.3 cigarettes per dayStandard Deviation 5.7
AC + tDCSMean Change From Baseline in Number Cigarettes Smoked Daily-1.7 cigarettes per dayStandard Deviation 5.4
AC + Sham tDCSMean Change From Baseline in Number Cigarettes Smoked Daily-3.0 cigarettes per dayStandard Deviation 6.9
Comparison: 2 X 2 ANOVAp-value: 0.57ANOVA
Primary

Mean Change From Baseline in Number Cigarettes Smoked Daily

Difference in mean number of cigarette smoker per day from pre-treatment (Baseline) to 1 month post treatment (follow-up). Lower number indicates greater reduction in cigarettes smoked.

Time frame: Baseline to approximately 6-weeks

Population: 3 participants (1 from AAT + tDCS, 1 from AA + sham tDCS, and 1 from AC + tDCS) were lost to follow-up.

ArmMeasureValue (MEAN)Dispersion
AAT + tDCSMean Change From Baseline in Number Cigarettes Smoked Daily-3.8 cigarettes per dayStandard Deviation 3.9
AAT + Sham tDCSMean Change From Baseline in Number Cigarettes Smoked Daily-5.5 cigarettes per dayStandard Deviation 3.8
AC + tDCSMean Change From Baseline in Number Cigarettes Smoked Daily-4.3 cigarettes per dayStandard Deviation 5.9
AC + Sham tDCSMean Change From Baseline in Number Cigarettes Smoked Daily-4.6 cigarettes per dayStandard Deviation 5
Comparison: 2 x 2 ANOVAp-value: 0.657ANOVA
Primary

Mean Change From Baseline in Rating Score for 5-item Confidence to Quit Questionnaire

Difference between Confidence to Quit rating from pre-treatment (Baseline) to 1 week post-treatment (follow-up)

Time frame: Baseline to approximately 2-weeks

ArmMeasureValue (MEAN)Dispersion
AAT + tDCSMean Change From Baseline in Rating Score for 5-item Confidence to Quit Questionnaire-4.4 score on a scaleStandard Deviation 28.4
AAT + Sham tDCSMean Change From Baseline in Rating Score for 5-item Confidence to Quit Questionnaire6.9 score on a scaleStandard Deviation 20.4
AC + tDCSMean Change From Baseline in Rating Score for 5-item Confidence to Quit Questionnaire6.6 score on a scaleStandard Deviation 17.8
AC + Sham tDCSMean Change From Baseline in Rating Score for 5-item Confidence to Quit Questionnaire20.0 score on a scaleStandard Deviation 23.1
Comparison: 2 x 2 ANOVA with Main effect p-values for tDCS and AAT reported in comments belowp-value: 0.852ANOVA
Primary

Mean Change From Baseline in Rating Score for 5-item Confidence to Quit Questionnaire

Difference between Confidence to Quit score from pre-treatment (Baseline) to post-treatment (re-test) scored 0-100. More positive score reflects an increase in confidence to quit smoking.

Time frame: Baseline to approximately 1-week

Population: Data is missing from 2 participants (1 from AAT + tDCS and 1 from AC + sham tDCS)

ArmMeasureValue (MEAN)Dispersion
AAT + tDCSMean Change From Baseline in Rating Score for 5-item Confidence to Quit Questionnaire1.0 score on a scaleStandard Deviation 18
AAT + Sham tDCSMean Change From Baseline in Rating Score for 5-item Confidence to Quit Questionnaire8.9 score on a scaleStandard Deviation 20
AC + tDCSMean Change From Baseline in Rating Score for 5-item Confidence to Quit Questionnaire3.0 score on a scaleStandard Deviation 18.6
AC + Sham tDCSMean Change From Baseline in Rating Score for 5-item Confidence to Quit Questionnaire27.1 score on a scaleStandard Deviation 24.3
Comparison: 2 x 2 ANOVAp-value: 0.254ANOVA
Primary

Mean Change From Baseline in Rating Score for 5-item Confidence to Quit Questionnaire

Difference between Confidence to Quit rating from pre-treatment (Baseline) to 1 month post-treatment (follow-up)

Time frame: Baseline to approximately 6-weeks

Population: 3 participants were lost to follow up (1 each in groups AAT + tDCS, AAT + sham tDCS, and AC+tDCS)

ArmMeasureValue (MEAN)Dispersion
AAT + tDCSMean Change From Baseline in Rating Score for 5-item Confidence to Quit Questionnaire2.8 score on a scaleStandard Deviation 24.5
AAT + Sham tDCSMean Change From Baseline in Rating Score for 5-item Confidence to Quit Questionnaire13.3 score on a scaleStandard Deviation 20
AC + tDCSMean Change From Baseline in Rating Score for 5-item Confidence to Quit Questionnaire12.2 score on a scaleStandard Deviation 22.4
AC + Sham tDCSMean Change From Baseline in Rating Score for 5-item Confidence to Quit Questionnaire22.8 score on a scaleStandard Deviation 24.8
Comparison: 2 x 2 ANOVAp-value: 0.732ANOVA
Primary

Mean Change From Baseline in Rating Score for Intent to Quit Questionnaire

Difference between Intent to Quit score from pre-treatment (Baseline) to post-treatment (re-test). Scale is rated 1-10 from 1= I have no thoughts about or interest in quitting smoking to 10= I have quit and will never go back A positive change score indicates an increased intention to quit.

Time frame: Baseline to approximately 1-week

Population: 2 participants are not included in the analyses due to missing data (1 from AAT + tDCS, 1 from AC + sham tDCS)

ArmMeasureValue (MEAN)Dispersion
AAT + tDCSMean Change From Baseline in Rating Score for Intent to Quit Questionnaire1.2 score on a scaleStandard Deviation 1
AAT + Sham tDCSMean Change From Baseline in Rating Score for Intent to Quit Questionnaire0.4 score on a scaleStandard Deviation 0.9
AC + tDCSMean Change From Baseline in Rating Score for Intent to Quit Questionnaire-0.2 score on a scaleStandard Deviation 0.8
AC + Sham tDCSMean Change From Baseline in Rating Score for Intent to Quit Questionnaire0.7 score on a scaleStandard Deviation 1.6
Comparison: 2 x 2 ANOVAp-value: 0.038ANOVA
Primary

Mean Change From Baseline in Rating Score for Intent to Quit Questionnaire

Difference between Intent to Quit score from pre-treatment (Baseline) to 1 week post-treatment (follow-up). Scale is rated 1-10 from 1= I have no thoughts about or interest in quitting smoking to 10= I have quit and will never go back A positive change score indicates an increased intention to quit.

Time frame: Baseline to approximately 2-weeks

ArmMeasureValue (MEAN)Dispersion
AAT + tDCSMean Change From Baseline in Rating Score for Intent to Quit Questionnaire1.3 score on a scaleStandard Deviation 1.2
AAT + Sham tDCSMean Change From Baseline in Rating Score for Intent to Quit Questionnaire0.9 score on a scaleStandard Deviation 0.6
AC + tDCSMean Change From Baseline in Rating Score for Intent to Quit Questionnaire-0.3 score on a scaleStandard Deviation 0.9
AC + Sham tDCSMean Change From Baseline in Rating Score for Intent to Quit Questionnaire1.1 score on a scaleStandard Deviation 1.5
Comparison: 2 x 2 ANOVAp-value: 0.029ANOVA
Primary

Mean Change From Baseline in Rating Score for Intent to Quit Questionnaire

Difference between Intent to Quit score from pre-treatment (Baseline) to 1 month post-treatment (follow-up). Scale is rated 1-10 from 1= I have no thoughts about or interest in quitting smoking to 10= I have quit and will never go back A positive change score indicates an increased intention to quit.

Time frame: Baseline to approximately 6-weeks

Population: Data from 3 participants (1 from AAT + tDCS, 1 From AAT + sham tDCS, and 1 from AC + tDCS) were lost to follow-up

ArmMeasureValue (MEAN)Dispersion
AAT + tDCSMean Change From Baseline in Rating Score for Intent to Quit Questionnaire1.4 score on a scaleStandard Deviation 1.3
AAT + Sham tDCSMean Change From Baseline in Rating Score for Intent to Quit Questionnaire1.3 score on a scaleStandard Deviation 1.4
AC + tDCSMean Change From Baseline in Rating Score for Intent to Quit Questionnaire0.6 score on a scaleStandard Deviation 1.7
AC + Sham tDCSMean Change From Baseline in Rating Score for Intent to Quit Questionnaire1.3 score on a scaleStandard Deviation 1.8
Comparison: 2 x 2 ANOVAp-value: 0.353ANOVA

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026